BioNet Asia est une société de biotechnologie privée franco-thaïlandaise

Se concentrant sur la découverte, la fabrication et la fourniture de vaccins vitaux. BioNet est à la pointe de l’innovation dans le domaine de la coqueluche en améliorant les vaccins anticoquelucheux à l’aide de la technologie de l’ADN recombinant.

Actualités BioNet

BioNet News

01 Apr 2024

BioNet presents at the World Vaccine Congress in Washington 2024

Join BioNet at the World Vaccine Congress 2024 April 1st-4th in Washington D.C. The WVC is the largest and most…

BioNet News

12 Mar 2024

BioNet Announces New Scientific Advisory Board Member Dr. William Gruber

We are pleased to announce the appointment of Dr. William Gruber as our new Scientific Advisory Board Member. Dr William…

BioNet News

07 Mar 2024

BioNet presents at the INMIS 2024 in San Jose, Costa Rica

BioNet is pleased to announce its participation in the 6th annual International Neonatology and Maternal Immunization Symposium (INMIS 2024), taking…

BioNet News

07 Mar 2024

BioNet Announces New Scientific Advisory Board Member Prof. Peter Openshaw

We are pleased to announce the appointment of Prof. Peter Openshaw as our new Scientific Advisory Board Member. Peter Openshaw…

BioNet News

06 Mar 2024

BioNet Announces New Scientific Advisory Board Member Dr. Norbert Pardi

We are pleased to announce the appointment of Dr. Norbert Pardi as our new Scientific Advisory Board Member. Dr Norbert…

BioNet News

12 Dec 2023

Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines

Highlights • Recombinant pertussis vaccine is safe for both mother and newborn. • There is effective transplacental antibody transfer to…

BioNet News

22 Jun 2023

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women

Highlights • Recombinant acellular pertussis vaccine is safe and immunogenic in pregnant women. • Vaccine formulations containing PTgen were non-inferior…

BioNet News

13 Feb 2023

Produire des médicaments et des vaccins en Occitanie : un ambitieux projet porté à Toulouse

Et si on produisait bientôt des médicaments et des vaccins en Occitanie ? Le CHU de Toulouse et ses partenaires…

All Bionet Asia News

Actualités Biotech

Biotech News

02 Apr 2024

Australia’s first purpose-built facility to deliver human challenge trials launches in Melbourne

The new facility will accelerate the development of novel medicines and vaccines. Australia’s first clinical trial facility specifically commissioned to…

Biotech News

20 Mar 2024

New DNA Origami Platform, DoriVac, Opens New Path for Designer Cancer Vaccine Development

The central ingredient of therapeutic cancer vaccines is antigens, which are preferentially produced or newly produced (neoantigens) by tumor cells…

Biotech News

11 Mar 2024

MIT scientists use a new type of nanoparticle to make vaccines more powerful

Study shows metal-organic particles can both deliver vaccines and act as an adjuvant to generate a strong immune response at…

Biotech News

04 Mar 2024

Innovative New Vaccine Technology Uses DNA Particles That Pretend To Be Viruses

Scientists hope the approach could make it easier to create vaccines against trickier viruses like HIV. A new vaccine against…

Biotech News

01 Mar 2024

Study reveals promising potential of Hexaplex vaccine in boosting flu protection

A recent study led by a research team from the University at Buffalo has introduced a new recombinant flu vaccine,…

Biotech News

22 Jan 2024

Oxford starts human testing of Nipah virus vaccine

Field lab assistants catch a bat in their net as they collect specimens for their Nipah virus research in the…

All Biotech News

Dans les news

Rejoignez les équipes Bionet-Asia

Voulez-vous rejoindre une équipe talentueuse de personnes passionnées par la création d’un avenir où les épidémies ne sont plus une menace pour l’humanité?

voir nos offres d'emploi

BioNet presents at the World Vaccine Congress in Washington 2024

BioNet Asia est une société de biotechnologie privée franco-thaïlandaise

Actualités BioNet

BioNet presents at the World Vaccine Congress in Washington 2024

BioNet Announces New Scientific Advisory Board Member Dr. William Gruber

BioNet presents at the INMIS 2024 in San Jose, Costa Rica

BioNet Announces New Scientific Advisory Board Member Prof. Peter Openshaw

BioNet Announces New Scientific Advisory Board Member Dr. Norbert Pardi

Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women

Produire des médicaments et des vaccins en Occitanie : un ambitieux projet porté à Toulouse

Actualités Biotech

Australia’s first purpose-built facility to deliver human challenge trials launches in Melbourne

New DNA Origami Platform, DoriVac, Opens New Path for Designer Cancer Vaccine Development

MIT scientists use a new type of nanoparticle to make vaccines more powerful

Innovative New Vaccine Technology Uses DNA Particles That Pretend To Be Viruses

Study reveals promising potential of Hexaplex vaccine in boosting flu protection

Oxford starts human testing of Nipah virus vaccine

Dans les news

Rejoignez les équipes Bionet-Asia

Nos partenaires

Thank you for visiting us. Please confirm that you are a healthcare professional.

BioNet Asia est une société de biotechnologie privée franco-thaïlandaise

Rejoignez les équipes Bionet-Asia

Hit enter to search or ESC to close